Monitoring of response to radiation therapy for human tumor xenografts using 99mTc-HL91 (4,9-diaza-3,3,10,10-tetramethyldodecan-2,11-dione dioxime)

Annals of Nuclear Medicine

Volumn 17, Issue 2, 2003, Pages 131-138

  Suzuki, Takayuki ^a   Nakamura, Kayoko ^a   Kawase, Takatsugu ^a   Kubo, Atsushi ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

99mTc HL91; Prediction; Radiation therapy; Radiosensitivity; Tumor hypoxia

Indexed keywords

4,9 DIAZA 3,3,10,10 TETRAMETHYLDODECANE 2,11 DIONE DIOXIME TECHNETIUM 99M; RADIOISOTOPE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTORADIOGRAPHY; BIOACCUMULATION; CANCER RADIOTHERAPY; CONTROLLED STUDY; DRUG TUMOR LEVEL; HUMAN; HUMAN CELL; HYPOXEMIA; LINEAR ACCELERATOR; MONITORING; MOUSE; NONHUMAN; OXYGENATION; PRIORITY JOURNAL; RADIATION DOSE; RADIOSENSITIVITY; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT;

EID: 0038659985     PISSN: 09147187     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02988451     Document Type: Article

References (20)

1. Gray LH, Conger AD, Ebert M, Hornsey S, Scott OCA. Concentration of oxygen dissolved in tissues at time of irradiation as a factor in radiotherapy. Br J Radiol 1953; 26: 638-648.
2. Moulder JE, Rockwell S. Tumor hypoxia: its impact on cancer therapy. Cancer Metastasis Rev 1987; 5: 313-341.
3. Hall EJ. The oxygen effect and Reoxygenation. In: Radiobiology for the Radiologist, Philadelphia; Lippincott Williams & Wilkins, 2000: 91-111.
4. Horsman MR. Nicotinamide and other Benzamide analogs a agents for overcoming hypoxic cell radiation resistance in tumors. Acta Oncologica 1995; 34: 571-587.
5. Brown JM. Tumor hypoxia, drug resistance, and metastases. J Natl Cancer Inst 1990; 82: 338-339.
6. Moulder JE, Rockwell S. Hypoxic fractions of solid tumors. Int J Radiat Oncol Biol Phys 1984; 10: 695-712.
7. Kallman RF. The phenomenon of reoxygenation and its implications for fractionated radiotherapy. Radiology 1972; 105:135-142.
8. Cook GJR, Barrington S, Houston S, Maisey MN, Fogelman I. HL91, a new Tc-99m-labelled agent with potential for identifying tumour hypoxia: correlation with FDG PET. J Nucl Med 1996; 37: 87-88.
9. 99mTc-BnAO (HL91): a nonnitroaromatic compound for hypoxic cell detection. Int J Radiat Oncol Biol Phys 1998; 42: 1-4.
10. 99mTc-HL91 (Prognox) in murine and xenograft systems in vivo. Int J Radiat Oncol Biol Phys 1998; 42: 731-735.
11. 99mTc-HL91, a putative hypoxic tracer, to detection of tumor hypoxia. J Nucl Med 1999; 40: 854-861.
12. 99mTc-HL91 (4,9-diaza-3,3,10,10-tetra methyldodecan-2,11-dione dioxime). KAKU IGAKU (Jpn J Nucl Med) 2001; 38: 333-341.
13. Hopkins HA, Ritenour ER, MacLeod MS, Looney WB. The effect of varying the time between irradiation and cyclophosphamide on growth response of hepatoma 3924A. Int J Radiat Oncol Biol Phys 1979; 5: 1455-1459.
14. Looney WB, Hopkins HA, Carter WH Jr. Solid tumor models for the assessment of different treatment modalities: XXIII. A new approach to the more effective utilization of radiotherapy alternated with chemotherapy. Int J Radiat Oncol Biol Phys 1985; 11: 2105-2117.
15. Chapman JD, Engelhardt EL, Stobbe CC, Schneider RF, Hanks GE. Measuring hypoxia and predicting tumor radioresistance with nuclear medicine assays. Radiother Oncol 1998;46:229-237.
16. Fukumoto M, Yoshida D, Hayase N, Kurohara A, Akagi N, Yoshida S. Scintigraphic prediction of resistance to radiation and chemotherapy in patients with lung carcinoma: technetium 99m-tetrofosmin and thallium-201 dual single photon emission computed tomography study. Cancer 1999; 86:1470-1479.
17. Ballinger JR, Kee JW, Rauth AM. In Vitro and In Vivo Evaluation of a Technetium-99m-Labeled 2-Nitroimidazole (BMS 181321) as a Marker of Tumor Hypoxia. J Nucl Med 1996;37:1023-1031.
18. 99mTc-Labeled 2-Nitroimidazole for Imaging Hypoxia in Tumors. J Nucl Med 2000; 41: 169-176.
19. Mannan RH, Somayaji VV, Lee J, Mercer JR, Chapman JD, Wiebe LI. Radioiodinated 1-(5-iodo-5-deoxy-beta-Darabinofuranosyl)-2-nitroimidazole (iodoazomycin arabinoside: IAZA): a novel marker of tissue hypoxia. J Nucl Med 1991; 32: 1764-1770.
20. 123I-iodoazomycin arabinoside: preliminary report of a clinical study. Br J Cancer 1992;65:90-95.